company background image
ATRC logo

AtriCure NasdaqGM:ATRC Stock Report

Last Price

US$23.78

Market Cap

US$1.1b

7D

8.9%

1Y

-55.4%

Updated

15 Jul, 2024

Data

Company Financials +

ATRC Stock Overview

Develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally.

ATRC fundamental analysis
Snowflake Score
Valuation5/6
Future Growth1/6
Past Performance0/6
Financial Health5/6
Dividends0/6

AtriCure, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for AtriCure
Historical stock prices
Current Share PriceUS$23.78
52 Week HighUS$59.61
52 Week LowUS$18.94
Beta1.44
11 Month Change14.55%
3 Month Change2.94%
1 Year Change-55.38%
33 Year Change-69.20%
5 Year Change-24.91%
Change since IPO68.89%

Recent News & Updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

Recent updates

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

May 30
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 88% Above Its Share Price

Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Apr 04
Positive Sentiment Still Eludes AtriCure, Inc. (NASDAQ:ATRC) Following 29% Share Price Slump

Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Mar 14
Does AtriCure (NASDAQ:ATRC) Have A Healthy Balance Sheet?

Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Jan 21
Investors Interested In AtriCure, Inc.'s (NASDAQ:ATRC) Revenues

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Nov 29
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Sep 27
AtriCure, Inc.'s (NASDAQ:ATRC) Intrinsic Value Is Potentially 99% Above Its Share Price

Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

Aug 02
Health Check: How Prudently Does AtriCure (NASDAQ:ATRC) Use Debt?

AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Jun 15
AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Matching Investor Opinion

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Apr 14
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

Mar 02
Calculating The Intrinsic Value Of AtriCure, Inc. (NASDAQ:ATRC)

What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Feb 09
What Does AtriCure, Inc.'s (NASDAQ:ATRC) Share Price Indicate?

Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Dec 28
Is AtriCure (NASDAQ:ATRC) Using Debt In A Risky Way?

Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

Sep 06
Is Now An Opportune Moment To Examine AtriCure, Inc. (NASDAQ:ATRC)?

An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

Aug 02
An Intrinsic Calculation For AtriCure, Inc. (NASDAQ:ATRC) Suggests It's 29% Undervalued

AtriCure: 5x Sales For A Series Of Impeding Losses? No Thanks

Jun 13

Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Jun 08
Is AtriCure (NASDAQ:ATRC) Weighed On By Its Debt Load?

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

May 08
Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Apr 11
Is AtriCure, Inc. (NASDAQ:ATRC) Expensive For A Reason? A Look At Its Intrinsic Value

Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Feb 18
Is AtriCure (NASDAQ:ATRC) A Risky Investment?

Shareholder Returns

ATRCUS Medical EquipmentUS Market
7D8.9%2.1%1.2%
1Y-55.4%-1.9%22.0%

Return vs Industry: ATRC underperformed the US Medical Equipment industry which returned -1.9% over the past year.

Return vs Market: ATRC underperformed the US Market which returned 22% over the past year.

Price Volatility

Is ATRC's price volatile compared to industry and market?
ATRC volatility
ATRC Average Weekly Movement8.4%
Medical Equipment Industry Average Movement7.8%
Market Average Movement5.8%
10% most volatile stocks in US Market14.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: ATRC has not had significant price volatility in the past 3 months.

Volatility Over Time: ATRC's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20001,200Mike Carrelwww.atricure.com

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure.

AtriCure, Inc. Fundamentals Summary

How do AtriCure's earnings and revenue compare to its market cap?
ATRC fundamental statistics
Market capUS$1.12b
Earnings (TTM)-US$37.23m
Revenue (TTM)US$414.60m

2.8x

P/S Ratio

-30.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ATRC income statement (TTM)
RevenueUS$414.60m
Cost of RevenueUS$102.57m
Gross ProfitUS$312.03m
Other ExpensesUS$349.26m
Earnings-US$37.23m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

Jul 30, 2024

Earnings per share (EPS)-0.77
Gross Margin75.26%
Net Profit Margin-8.98%
Debt/Equity Ratio13.6%

How did ATRC perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.